Alnylam Pharmaceuticals | ALNY - Operating Profit

Stock Price
331.70
Daily Change
-20.26 -5.76%
Monthly
-18.38%
Yearly
19.21%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $-29.96M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 44.11M 209.66M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.58B 879M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Takeda JPY 168.82B 479.89B Dec/2025
Tectonic Therapeutic USD -21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xencor USD -47.52M 14.35M Sep/2025